Multiple endocrine neoplasia type 2 historical perspective
|
Multiple endocrine neoplasia type 2 Microchapters |
|
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Multiple endocrine neoplasia type 2 historical perspective On the Web |
|
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 historical perspective |
|
FDA on Multiple endocrine neoplasia type 2 historical perspective |
|
CDC on Multiple endocrine neoplasia type 2 historical perspective |
|
Multiple endocrine neoplasia type 2 historical perspective in the news |
|
Blogs on Multiple endocrine neoplasia type 2 historical perspective |
|
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
|
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Historical Perspective
- Historical background of multiple endocrine neoplasia type 2 is given in the table below.
| Years | Scientist | Contribution |
|---|---|---|
| 1954 | Wermer | Reported that syndrome was transmitted as a dominant trait |
| 1959 | Hazard | Described medullary (solid) thyroid carcinoma |
| 1961 | Sipple | Described a combination of a pheochromocytoma, medullary thyroid carcinoma and parathyroid adenoma |
| 1965 | Schimke and Hartmann | Described a syndrome of medullary thyroid carcinoma with abundant amyloid stroma and pheochromocytoma [1] |
| 1966 | Williams | Reported a case of a patient with combination of mucosal neuromas, pheochromocytoma and medullary thyroid carcinoma |
| 1968 | Steiner | Introduced the term "multiple endocrine neoplasia" (MEN) to describe disorders featuring combinations of endocrine tumors and proposed the terms 'Wermer syndrome' for MEN 1 and 'Sipple syndrome' for MEN 2 |
| Meyer and Abdel-Bari | Suggested that medullary carcinoma produces thyrocalcitonin from parafollicular cells | |
| 1970 | Kaplan | Adrenal medulla produces a calcitonin like material[2] |
| 1974 | Sizemore | Showed that the MEN 2 category included two groups of patients with MTC and pheochromocytoma: one with parathyroid disease and a normal appearance (MEN 2A) and the other without parathyroid disease but with mucosal neuromas and mesodermal abnormalities (MEN 2B) |
| 1978 | Hamilton | Reported a case of Zollinger Ellison syndrome in multiple endocrine hyperplasia type 2 |
| Cameron | Suggested that medullary carcinoma produces thyrocalcitonin from parafollicular cells[3] | |
| 1980 | Le Marec | Congential megacolon in sipple syndrome[4] |
| 1989 | Sobol | Proposed that restriction fragment length polymerase is useful in predicting the carrier state of multiple endocrine neoplasia syndrome |
| 1993 | RET germline mutations were recognized as the causative molecular alterations in MEN 2 syndromes | |
| 1998 | MEN1 gene was cloned[5] | |
| 2001 | Koch | Introduced the 2 hit mechanism for MEN 2 associated tumors and also described the mechanism of involved in trisomy 10 |
References
- ↑ Schimke RN, Hartmann WH (1965). "Familial amyloid-producing medullary thyroid carcinoma and pheochromocytoma. A distinct genetic entity". Ann Intern Med. 63 (6): 1027–39. PMID 5844561.
- ↑ Kaplan EL, Arnaud CD, Hill BJ, Peskin GW (1970). "Adrenal medullary calcitonin-like factor: a key to multiple endocrine neoplasia, type 2?". Surgery. 68 (1): 146–9. PMID 10483461.
- ↑ Cameron D, Spiro HM, Landsberg L (1978). "Zollinger-Ellison syndrome with multiple endocrine adenomatosis type II". N Engl J Med. 299 (3): 152–3. doi:10.1056/NEJM197807202990315. PMID 26873.
- ↑ Le Marec B, Roussey M, Cornec A, Calmettes C, Kerisit J, Allanic H (1981). "[Thyroid cancer with amyloid stroma, Sipple's syndrome, congenital megacolon with plexus hyperplasia: one and the same dominant autosomal disease with complete penetrance]". J Genet Hum. 28 (5): 169–74. PMID 7276917.
- ↑ Guru SC, Manickam P, Crabtree JS, Olufemi SE, Agarwal SK, Debelenko LV. Identification and characterization of the multiple endocrine neoplasia type 1 (MEN1) gene. J Intern Med 243(6) 433-9